2020 Event Archive

Post-Event Report from Chairman

Our 2020 meeting was conducted via a virtual platform which afforded us the chance to hear from speakers based in Germany, Canada, USA and even… Aberdeen. All are well-known at an international level in their respective fields and therefore we were extremely lucky to have the opportunity to hear about their work on a range of topics, including cardiovascular risk estimation, lipid genetics and novel therapeutics.

Professor Stefan Blankenberg (UKE, Hamburg) presented his international consortium’s work on calculation of long-term cardiovascular risk using non-HDL cholesterol, established using an impressively large but high-quality dataset.  Professor Robert Hegele (University Hospital, London, Ontario) gave a superb account of hypobetalipoproteinaemia, underlining how establishing the basis for rare inherited disorders can lead to significant advances in the diagnosis and therapy for a range of dyslipidaemias. Dr Jaimini Cegla (Imperial College London, UK) delivered an excellent presentation on Lp(a), explaining some of the analytical issues involved in its measurement and outlining a way forward for incorporating Lp(a) into cardiovascular risk assessment. Professor Zosia Miedzybrodzka (NHS Grampian, University of Aberdeen) provided an update on Scottish progress with FH genetic screening, and also presented data pointing to gaps in FH management. And for our final talk, we were extremely fortunate to hear from Professor Scott Wright (Mayo Clinic, USA) who presented the latest on phase III trials for Inclisiran, set against a historical context of lipid-lowering therapy. We can only hope that next year’s meeting will be half as good!


The Scottish Lipid Forum 2020 programme can be found here.

SLF Prize

Content to be uploaded.


Scottish Lipid Forum are grateful to each of our sponsors, without whose financial sponsorship this meeting would not be possible. However, sponsors were not involved in the selection of speakers, topics or the organisation of the meeting.

Speaker Biographies

Prof Stefan Blankenberg

Occupation:    Medical Director & Director of the Clinical Cardiology
University Heart & Vascular Center, Hamburg UKE

He is a board member of the German Society of Cardiology and the German Society of Inner Medicine; speaker of the Work Group “Clinical Epidemiology” of the German Society of Cardiology; member of several international committees; ESC fellow; steering Committee member of the MORGAM Study, the LIPID Study and the Gutenberg Health Study and Hamburg City Health Study. Furthermore he is coordinator of the BiomarCaRE Project, a research project co-funded under the European Union’s Seventh Framework Programme. His main research interest is focused on individualized cardiovascular medicine with particular focus on acute coronary syndrome and heart failure. Stefan Blankenberg has published numerous papers in journals like NEJM, Nature Genetics, JAMA, Circulation, JACC and European Heart Journal.

Dr Jaimini Cegla

Occupation:     Consultant in Metabolic Medicine
       Imperial College Healthcare NHS Trust

Jaimini Cegla is a Consultant in Metabolic Medicine at Imperial College Healthcare NHS Trust, London, UK. She has a specialist interest in lipidology and cardiovascular risk and splits her time between clinical, laboratory and academic research roles. In her clinical role she looks after the Hammersmith Hospital Lipid Service, a one-stop centre for the genetic diagnosis and management of lipid disorders. Her current research focuses on cardiovascular risk including clinical trials of novel therapeutic agents. Dr Cegla is a member of the Medical, Scientific and Research Committee of HEART UK, the cholesterol charity. She also sits on the National Cardiovascular Disease Prevention System Leadership Forum, the advisory group of Public Health England for strategy on cardiovascular disease prevention.

Professor Rob Hegele

Occupation:     Staff Endocrinologist
Institution:       Department of Medicine, Western University, London, Canada

Rob Hegele is a staff endocrinologist who cares for > 2500 patients at the lipid clinic at University Hospital, London Ontario.

He was first in North America to use 5 medications that are now routinely prescribed to treat high cholesterol or diabetes.

He has published 780 papers, which have been cited >33,000 times and is in the Clarivate top 1% of highly cited scientists.  The website expertscape.com in 2020 ranked him #1 globally in the area of “hypertriglyceridemia” and #2 for “disorders of lipid metabolism”.   He received the 2019 American Heart Association Lyman Duff Award and the 2020 FH Foundation Pioneer Award.

He has co-authored many clinical practice guidelines for cholesterol, blood pressure and diabetes. He has trained numerous physicians, medical students and graduate students.

Prof Zosia Miedzybrodzka

No information available.

Dr. R. Scott Wright

Occupation:     Professor of Medicine and Consultant
Department of Cardiovascular Medicine at Mayo Clinic

Dr. R. Scott Wright is a Professor of Medicine and a Consultant in Cardiology at the Mayo Clinic in Rochester, MN USA.  His work at Mayo Clinic has focused on Acute Coronary Syndromes, Preventive Cardiology and Clinical Trial design and research.

Dr. Wright graduated with his bachelor’s degree and his Doctorate of Medicine from the University of Kentucky and did his post-medical school training in Internal Medicine, Clinical Investigation and Fellowship in Cardiovascular diseases at the Mayo Clinic in Rochester, MN.

Professor Wright has authored over 100 original articles and book chapters in the field of cardiovascular medicine. He has worked on a large number of clinical trials and has been a member of the Steering Committee of many of them. He chaired the CCU Database for 8 years at Mayo Clinic leading efforts to analyze and publish Mayo Clinic’s experience in acute ischemic heart disease.  He has also held a number of administrative roles within the Division of Cardiology at Mayo Clinic including Director of Marketing, Director of Outreach services and director of the Mayo Health System Cardiovascular Task Force. He has chaired an Institutional Review Board at Mayo Clinic for many years and also chairs the Pharmacy and Therapeutics Cardiovascular Task Force. He is currently the Senior IRB chair at Mayo Clinic and Director of the Human Research Protection Program.

Speaker Presentations

Non-HDL-C & lifetime CV risk

Content to be uploaded.

Lp(a): measurement and clinical application

Content to be uploaded.


Content to be uploaded.

Scottish genetics update

Content to be uploaded.

Inclisiran update

Content to be uploaded.


“Virtual allows attendance of part of the meeting when clinical commitments mean it would otherwise be impossible.”

Testimonial from SLF Delegate

“Top class international faculty”

Testimonial from SLF Delegate

“Fantastic presenters and talks throughout and a big turnout which is great. Glad to see so many people taking an interest in lipids and CVD prevention.”

Testimonial from Exhibitor

“The agendas and speakers were fantastic as ever!”

Testimonial from Exhibitor

“The calibre of speakers was absolutely first class, and all of them presented excellent presentations and were in themselves very good speakers.”

Testimonial from Exhibitor